Cvent, Inc. (NYSE:CVT) shares advanced 0.75% in last trading session and ended the day at $34.80. CVT Gross Margin is 67.70% and its has a return on assets of -3.00%. Cvent, Inc. (NYSE:CVT) quarterly performance is 2.96%.
Digital Realty Trust Inc. (NYSE:DLR) ended the last trading day at $76.10. Company weekly volatility is calculated as 1.24% and price to cash ratio as 484.19. Digital Realty Trust Inc. (NYSE:DLR) showed a weekly performance of 1.74%.
On 16 December, Digital Realty Trust, Inc. (NYSE:DLR), a leading global provider of data center solutions, announced that it has earned the U.S. Environmental Protection Agency (EPA)’s ENERGY STAR certification for its data center in Lithia Springs, Georgia. This certification indicates that the facility performs in the top 25 percent of similar facilities nationwide for energy efficiency and meets the strict energy efficiency performance levels set by the EPA.
On 28 December, Chesapeake Lodging Trust (NYSE:CHSP) shares fell -0.58% and was closed at $25.61. CHSP EPS growth in last 5 year was 34.28%. Chesapeake Lodging Trust (NYSE:CHSP) year to date (YTD) performance is -28.62%.
Chesapeake Lodging Trust (NYSE:CHSP) announced that its board of trustees has declared a quarterly dividend payment of $0.40 per common share. The dividend will be paid on January 15, 2016 to shareholders of record at the close of business on December 31, 2015.
Jones Energy, Inc. (NYSE:JONE) shares fell -10.71% in last trading session and ended the day at $3.75. JONE Gross Margin is 76.30% and its has a return on assets of 1.40%. Jones Energy, Inc. (NYSE:JONE) quarterly performance is -23.63%.
JPMorgan Chase & Co. began coverage on shares of Jones Energy Inc (NYSE:JONE) in a report released on Wednesday, The Fly reports. The brokerage issued an overweight rating and a $6.00 price objective on the oil and gas exploration company’s stock.
Loxo Oncology, Inc. (NASDAQ:LOXO) caters to the Healthcare space. Its weekly performance is -8.17%. On the last day of trading company shares ended up at $29.33. Loxo Oncology, Inc. (NASDAQ:LOXO) distance from 50-day simple moving average (SMA50) is -1.53%.
On 22 December, Loxo Oncology, Inc. (NASDAQ:LOXO), announced the enrollment of the first patient in its Phase 1 trial of LOXO-101 in pediatric patients with advanced solid or primary central nervous system (CNS) tumors. LOXO-101 is the only selective inhibitor of the tropomyosin receptor kinase (TRK) protein family in clinical development.
Leave a Reply